Potentials for the use of glucocorticosteroids in inpatients with severe COVID-19

DOI: https://dx.doi.org/10.18565/pharmateca.2021.10.10-16

V.M. Tsvetov (1), A.V. Matveev (2), K.B. Mirzaev (2), V.A. Otdelnov (2), D.A. Sychev (2)

1) Federal Center for Cardiovascular Surgery, Chelyabinsk, Russia; 2) Russian Medical Academy of Continuous Professional Education, Moscow, Russia
Systemic glucocorticosteroids (GCSs) reduce mortality and prevent disease progression in patients with severe new coronavirus infection (COVID-19) and critically ill patients on oxygen support. This has been proven in systematic reviews of clinical trials and is recommended by the guidelines of the WHO, the Ministry of Health of the Russian Federation, and health authorities of foreign countries. Systemic GCSs should only be recommended for patients on oxygen support and should not be recommended for patients who do not require oxygen therapy. We have found insufficient studies comparing GCSs with interleukin-6 receptor inhibitors or Janus kinase inhibitors in order to speak of the superiority of this or that strategy, but in the absence of these biological drugs, GCSs can be considered as an alternative for severe COVID-19 patients on oxygen support.
Keywords: coronavirus infection (COVID-19), systemic glucocorticoids, oxygen therapy

About the Autors

Corresponding author: Vitaliy M. Tsvetov, Cand. Sci. (Med.), Federal Center for Cardiovascular Surgery, Chelyabinsk, Russia
Address: 2, Prospect Hero of Russia Evgeny Rodionov, Chelyabinsk 454003, Russian Federation  

Бионика Медиа